Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Soligenix Inc is a biotechnology business based in the US. Soligenix shares (SNGX) are listed on the NASDAQ and all prices are listed in US Dollars. Soligenix employs 13 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.58 |
|---|---|
| 52-week range | $0.38 - $1.32 |
| 50-day moving average | $0.54 |
| 200-day moving average | $0.74 |
| Wall St. target price | $3.88 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.35 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.58 from 2022-07-01
| 1 week (2022-06-28) | 7.41% |
|---|---|
| 1 month (2022-06-03) | 13.73% |
| 3 months (2022-04-05) | -20.55% |
| 6 months (2022-01-05) | -15.94% |
| 1 year (2021-07-02) | -44.23% |
|---|---|
| 2 years (2020-07-02) | -70.41% |
| 3 years (2019-07-05) | 0.785 |
| 5 years (2017-07-05) | 2.05 |
| Revenue TTM | $864,738 |
|---|---|
| Gross profit TTM | $95,628 |
| Return on assets TTM | -34.2% |
| Return on equity TTM | -121.64% |
| Profit margin | 0% |
| Book value | $0.15 |
| Market capitalisation | $25 million |
TTM: trailing 12 months
We're not expecting Soligenix to pay a dividend over the next 12 months.
Soligenix's shares were split on a 1:10 basis on 6 October 2016. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Soligenix shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Soligenix shares which in turn could have impacted Soligenix's share price.
Over the last 12 months, Soligenix's shares have ranged in value from as little as $0.38 up to $1.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Soligenix's is 1.2713. This would suggest that Soligenix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Soligenix, Inc. , a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.